CEVEC NEWS

ROKOTE LABORATORIES LICENSES CEVEC’S CAP® AD TECHNOLOGY FOR VACCINE MANUFACTURING

  • ROKOTE Laboratories Finland Ltd to use CEVEC’s CAP® Ad viral vector technology for manufacturing therapeutic and prophylactic vaccines for COVID-19 and other respiratory diseases
  • By eliminating the risk of RCA contaminations, CAP® Ad-derived viral vectors provide highest safety, addressing one of the major challenges in vector-based vaccine production

Cologne, Germany and Helsinki and Kuopio, Finland – September 20, 2022

KEEP IN TOUCH

Subscribe to receive CEVEC’s latest Press Releases, Conference Information and Webinar Invitations according to our Privacy Policy.

© CEVEC Pharmaceuticals GmbH 2022